{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:41:44Z","timestamp":1784241704126,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,11,21]],"date-time":"2006-11-21T00:00:00Z","timestamp":1164067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s10495-006-0492-z","type":"journal-article","created":{"date-parts":[[2006,11,29]],"date-time":"2006-11-29T21:53:33Z","timestamp":1164837213000},"page":"73-85","source":"Crossref","is-referenced-by-count":33,"title":["TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract"],"prefix":"10.1007","volume":"12","author":[{"given":"Anil","family":"Sadarangani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumie","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Villal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lipkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Cuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth I.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,21]]},"reference":[{"key":"492_CR1","unstructured":"Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A (1999) Control of apoptosis signalling by Apo2 ligand. Recent Prog Horm Res 54:225\u201334"},{"key":"492_CR2","doi-asserted-by":"crossref","unstructured":"Gibson SB (2004) Epidermal growth factor and TRAIL interactions in epithelial-derived cells. Vitam Horm 67:207\u201327","DOI":"10.1016\/S0083-6729(04)67012-9"},{"key":"492_CR3","doi-asserted-by":"crossref","unstructured":"Wajant H, Gerspach J, Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55\u20136","DOI":"10.1016\/j.cytogfr.2004.12.001"},{"key":"492_CR4","doi-asserted-by":"crossref","unstructured":"de Thonel A, Eriksson JE (2005) Regulation of death receptors-Relevance in cancer therapies. Toxicol Appl Pharmaco 207:123\u201332","DOI":"10.1016\/j.taap.2005.03.032"},{"key":"492_CR5","doi-asserted-by":"crossref","unstructured":"Ling J, Herbst RS, Mendelson DS et\u00a0al (2006) Apo2L\/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma Journal of Clinical Oncology (Meeting Abstracts); ASCO Annual Meeting Proceedings Part I 24: 3047","DOI":"10.1200\/jco.2006.24.18_suppl.3047"},{"key":"492_CR6","unstructured":"Kanzler S, Trarbach T, Heinemann V et\u00a0al (2005) Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). ECCO 13 \u2014 the European Cancer Conference, Abstract 630"},{"key":"492_CR7","unstructured":"Bonomi P, Greco FA (2005). Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/recurrent non-small cell lung cancer. 11th World Conference on Lung Cancer: Abstract 1851"},{"key":"492_CR8","doi-asserted-by":"crossref","unstructured":"Sheridan JP, Marsters SA, Pitti RM et\u00a0al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818\u20131","DOI":"10.1126\/science.277.5327.818"},{"key":"492_CR9","doi-asserted-by":"crossref","unstructured":"Baetu TM, Hiscott J (2002) On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13:199\u201307","DOI":"10.1016\/S1359-6101(02)00006-0"},{"key":"492_CR10","unstructured":"Cuello M, Ettenberg SA, Clark AS et\u00a0al (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892\u2013900"},{"key":"492_CR11","doi-asserted-by":"crossref","unstructured":"Vignati S, Codegoni A, Polato F, Broggini M (2002) Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 38(1):177\u201383","DOI":"10.1016\/S0959-8049(01)00345-8"},{"key":"492_CR12","unstructured":"Leverkus M, Neumann M, Mengling T et\u00a0al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553\u201359"},{"key":"492_CR13","doi-asserted-by":"crossref","unstructured":"Roth W, Isenmann S, Naumann U et\u00a0al (1999) Locoregional Apo2L\/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265:479\u201383","DOI":"10.1006\/bbrc.1999.1693"},{"key":"492_CR14","doi-asserted-by":"crossref","unstructured":"Ashkenazi A, Pai RC, Fong S et\u00a0al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155\u201362","DOI":"10.1172\/JCI6926"},{"key":"492_CR15","doi-asserted-by":"crossref","unstructured":"Walczak H, Miller RE, Ariail K et\u00a0al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157\u201363","DOI":"10.1038\/5517"},{"key":"492_CR16","doi-asserted-by":"crossref","unstructured":"Kato S, Pinto M, Carvajal A et\u00a0al (2005) Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost 94:444\u201353","DOI":"10.1160\/TH05-01-0066"},{"key":"492_CR17","doi-asserted-by":"crossref","unstructured":"Auersperg N, Siemens CH, Myrdal SE (1984) Human ovarian surface epithelium in primary culture. In Vitro 20:743\u201355","DOI":"10.1007\/BF02618290"},{"key":"492_CR18","doi-asserted-by":"crossref","unstructured":"Verdugo P, Langley L, Aitken ML, Villalon M (1990) Development of an in vitro model of primate cervical goblet cells. Biorheology 27:465\u201370","DOI":"10.3233\/BIR-1990-273-425"},{"key":"492_CR19","unstructured":"Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K (1985) Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37:1103\u2013111"},{"key":"492_CR20","unstructured":"Kuramoto H (1972) Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn 19:47\u20138"},{"key":"492_CR21","unstructured":"Louie KG, Behrens BC, Kinsella TJ et\u00a0al (1985) Radiation survival parameters of antineoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110\u2013115"},{"key":"492_CR22","doi-asserted-by":"crossref","unstructured":"Eagle H (1955) Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 89:362\u201364","DOI":"10.3181\/00379727-89-21811"},{"key":"492_CR23","doi-asserted-by":"crossref","unstructured":"Cuello M, Ettenberg SA, Nau MM, Lipkowitz S (2001) Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81:380\u201390","DOI":"10.1006\/gyno.2001.6194"},{"key":"492_CR24","unstructured":"KeaneMM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791\u2013798"},{"key":"492_CR25","unstructured":"Li L, Heldin NE, Grawe J, Ulmsten U, Fu X (2004) Induction of apoptosis or necrosis in human endometrial carcinoma cells by 2-methoxyestradiol. Anticancer Res 24:3983\u2013990"},{"key":"492_CR26","doi-asserted-by":"crossref","unstructured":"Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156\u201359","DOI":"10.1016\/0003-2697(87)90021-2"},{"key":"492_CR27","unstructured":"Thigpen T, Vance RB, Khansur T (1995) The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cerviz. Semin Oncol 22:67\u20135"},{"key":"492_CR28","doi-asserted-by":"crossref","unstructured":"Dolcet X, Llobet D, Pallares J et\u00a0al (2005) FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 85:885\u201394","DOI":"10.1038\/labinvest.3700286"},{"key":"492_CR29","doi-asserted-by":"crossref","unstructured":"Horak P, Pils D, Haller G et\u00a0al (2005) Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3:335\u201343","DOI":"10.1158\/1541-7786.MCR-04-0136"},{"key":"492_CR30","unstructured":"Li CM, Peng ZL, Yang KX (2005) The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer Sichuan Da Xue Xue Bao Yi Xue Ban 36:341\u201343"},{"key":"492_CR31","doi-asserted-by":"crossref","unstructured":"Kelley RF, Totpal K, Lindstrom SH et\u00a0al (2005) Receptor-selective mutants of apoptosis-inducing ligand 2\/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205\u2013212","DOI":"10.1074\/jbc.M410660200"},{"key":"492_CR32","doi-asserted-by":"crossref","unstructured":"Vincent H, Claire PP, Marion T et\u00a0al (2006) Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 66:987\u201395","DOI":"10.1002\/pros.20421"},{"key":"492_CR33","doi-asserted-by":"crossref","unstructured":"Reesink-Peters N, Hougardy BM, Van Den Heuvel FA et\u00a0al (2005) Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96:705\u201313","DOI":"10.1016\/j.ygyno.2004.10.046"},{"key":"492_CR34","doi-asserted-by":"crossref","unstructured":"Lelle RJ, Talavera F, Gretz et\u00a0al (1993) Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer 72:519\u201325","DOI":"10.1002\/1097-0142(19930715)72:2<519::AID-CNCR2820720231>3.0.CO;2-#"},{"key":"492_CR35","unstructured":"Yaginuma Y, Westphal H (1991) Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51: 6506\u2013509"},{"key":"492_CR36","unstructured":"Matsushima-Nishiu M, Unoki M, Ono K et\u00a0al (2001) Growth and gene expression profile analysis of endometrial cancer cell lines expressing exogenous PTEN. Cancer Res 61:3741\u2013749"},{"key":"492_CR37","unstructured":"Lilja JF, Wu D, Reynolds RK et\u00a0al (2001) Growth suppression activity of the PTEN tumor suppressor gene in human endometrial cancer cells. Anticancer Res 21:1969\u2013974"},{"key":"492_CR38","doi-asserted-by":"crossref","unstructured":"Boyd J, Risinger JI (1991) Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog 4:189\u201395","DOI":"10.1002\/mc.2940040305"},{"key":"492_CR39","doi-asserted-by":"crossref","unstructured":"Nesterov A, Lu X, Johnson M et\u00a0al (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276:10767\u20130774","DOI":"10.1074\/jbc.M005196200"},{"key":"492_CR40","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG (2003) Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278:33753\u20133762","DOI":"10.1074\/jbc.M303313200"},{"key":"492_CR41","doi-asserted-by":"crossref","unstructured":"Keane MM, Rubinstein Y, Cuello M et\u00a0al (2000) Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64:211\u201319","DOI":"10.1023\/A:1006458407515"},{"key":"492_CR42","doi-asserted-by":"crossref","unstructured":"LeBlanc H, Lawrence D, Varfolomeev E et\u00a0al (2002) Tumor-cell resistance to death receptor\u2013induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274\u201381","DOI":"10.1038\/nm0302-274"},{"key":"492_CR43","doi-asserted-by":"crossref","unstructured":"Sharp DA, Lawrence DA, Ashkenazi A (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280:19401\u20139409","DOI":"10.1074\/jbc.M413962200"},{"key":"492_CR44","unstructured":"Leverkus M, Neumann M, Mengling T et\u00a0al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553\u201359"},{"key":"492_CR45","doi-asserted-by":"crossref","unstructured":"Kumar SR, Singh J, Xia G et\u00a0al (2006) Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279\u201393.","DOI":"10.2353\/ajpath.2006.050889"},{"key":"492_CR46","doi-asserted-by":"crossref","unstructured":"Jo M, Kim TH, Seol DW (2000) Apoptosis induced in normal hepatocytes by tumor necrosis factor-realted apoptosis-inducing ligand. Nat Med 6:564\u201367","DOI":"10.1038\/75045"},{"key":"492_CR47","doi-asserted-by":"crossref","unstructured":"Nitsch R, Bechmann I, Deisz RA (2000) Human brain-cell death induced by tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL). Lancet 356:827\u201328","DOI":"10.1016\/S0140-6736(00)02659-3"},{"key":"492_CR48","doi-asserted-by":"crossref","unstructured":"Lawrence D, Shahrokh Z, Marsters S (2001) Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions. Nat Med 7:383\u201385","DOI":"10.1038\/86397"},{"key":"492_CR49","doi-asserted-by":"crossref","unstructured":"Qin J, Chaturvedi V, Bonish B, Nickoloff BJ (2001) Avoiding premature apoptosis of normal epithelial cells. Nat Med 7:385\u201386","DOI":"10.1038\/86401"},{"key":"492_CR50","doi-asserted-by":"crossref","unstructured":"Cuello M, Coats AO, Darko I et\u00a0al (2004) N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 11(5):527\u201341","DOI":"10.1038\/sj.cdd.4401387"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-0492-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-006-0492-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-006-0492-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T04:17:36Z","timestamp":1587269856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-006-0492-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s10495-006-0492-z","relation":{},"ISSN":["1573-675X"],"issn-type":[{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,21]]}}}